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A B S T R A C T
Mesenchymal stromal cells (MSC) are used for cell-based treatment for canine osteoarthritis (OA).
Compared with human MSCs, detailed information on the functional characterisation of canine MSCs is
limited. In particular, the chondrogenic differentiation of canine adipose tissue-derived MSCs (cAT-MSCs)
is challenging. In this study, we aimed to compare cAT-MSCs with bone marrow-derived MSCs (cBM-
MSCs), focusing specifically on their in vitro chondrogenic potential, with or without bone
morphogenetic proteins (BMP). cBM-MSCs and cAT-MSCs were characterised using flow cytometry
and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The chondrogenic
differentiation potential of all cMSC preparations in the presence of TGF-β1 alone or when supplemented
with 10, 100, or 250 ng/mL BMP-2 or BMP-6 was investigated using RT-qPCR, and biochemical,
histochemical and immunohistological analyses.
Both cBM-MSCs and cAT-MSCs expressed the surface markers CD90, CD73, and CD29, and were
negative for CD45 and CD34, although the expression of CD73 and CD271 varied with donor and tissue
origin. Interestingly, expression of ACAN and SOX9 was higher in cBM-MSCs than cAT-MSCs. In contrast
with cBM-MSCs, cAT-MSCs could not differentiate toward the chondrogenic lineage without BMP-2/-6,
and their in vitro chondrogenesis was inferior to cBM-MSCs with BMP-2/-6. Thus, cAT-MSCs have lower
in vitro chondrogenic capacity than cBM-MSC under the studied culture conditions with 10, 100, or 250
ng/mL BMP-2 or BMP-6. Therefore, further characterisation is necessary to explore the potential of cAT-
MSCs for cell-based OA treatments.
© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Osteoarthritis (OA) is a common progressive joint disease,
characterised by cartilage degradation, subchondral bone changes,
and synovial inflammation. OA affects 2.5%–20% of the canine
population, which increases to 80% in dogs aged >8 years
(Anderson et al., 2018). Mesenchymal stromal cells (MSCs) are
promising candidates for cell-based OA treatments because of their
immunomodulatory properties and chondrogenic capacity (Whit-
worth and Banks, 2014; Im, 2018). Human MSCs isolated from the
bone marrow (hBM-MSCs) possess in vitro chondrogenic potential
(Johnstone et al., 1998; Pelttari et al., 2008). Compared to hBM-
MSCs, human MSCs isolated from the adipose tissue (hAT-MSC)
possess several advantages, including ease of isolation with
minimal morbidity, relatively higher MSC concentration (Oedayr-
ajsingh-Varma et al., 2006), higher proliferation rate (Schäffler and
Büchler, 2007), and stronger immunosuppressive capabilities
(Mattar and Bieback, 2015). While hAT-MSCs can differentiate
toward multiple lineages in vitro and in vivo, their osteogenic and
chondrogenic potential are inferior to those of hBM-MSCs (Strioga
et al., 2012).
Canine MSCs (cMSCs) have been less extensively characterised
than hMSCs (de Bakker et al., 2013). Particularly, the chondrogenic
differentiation of cAT-MSCs is challenging; chondrogenesis in
earlier studies was either unsuccessful (Russell et al., 2016),
inferior to that of cBM-MSCs (Reich et al., 2012; Bearden et al.,
2017), or lacked robust evidence (Robey, 2017).
Therefore, we aimed to enhance the chondrogenic capacity of
cAT-MSCs to the level exhibited by cBM-MSCs by supplementing
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xpression, which is otherwise downregulated in hAT-MSCs
ompared to that in hBM-MSCs, thereby recovering the effect of
GF-β1 on hAT-MSC chondrogenesis (Hennig et al., 2007).
dditionally, (surface) marker expression levels in cAT-MSCs and
BM-MSCs were compared for obtaining more insights regarding
ifferences in cell population.
aterials and methods
nimal samples
Bone marrow and adipose tissue samples were collected from
ealthy dogs (n = 14) after euthanasia for unrelated experiments
Appendix A: Supplementary material). The protocol was approved
y the Ethics Committee on Animal Experimentation of Utrecht
niversity (2012.III.07.068, 2013.III.08.254, 2013.III.08.054).
solation of cMSCs from the bone marrow and adipose tissue
cBM-MSCs and cAT-MSCs were isolated and expanded as per
ethods described previously (Tryfonidou et al., 2014; Malagola
t al., 2016). Briefly, after isolation, the cells were plated (cBM-MSCs;
.3–2  106 cells/cm2, cAT-MSCs: 4  104 cells/cm2) in MSC-
xpansion medium (α-MEM, Invitrogen) containing 10% foetal
ovine serum (FBS; Gibco, high performance), 1% penicillin/
treptomycin (P/S; GE Healthcare Life Sciences), 0.1 mM ascorbic
cid 2-phosphate (Sigma),and 1 ng/mLbasic fibroblast growth factor
bFGF; AbD Serotec) until confluency was reached and the cells were
ryopreserved until further use. Detailed description is provided in
ppendix A: Supplementary material.
olony-forming unit-fibroblast (CFU-F) assay
Cryopreserved cells were thawed on ice and plated in expansion
edium at a density of 17 cells/cm2 (corresponding to approxi-
ately 1000 cells/Petri dish (CellStar, 664160, Greiner Bio-One).
fter 10–14 days, the cells were fixed with methanol and stained
ith Crystal Violet (0.5% in methanol (100%), Sigma) for 15 min at
oom temperature (RT). After rinsing, the colonies (consisting of
50 cells) were counted.
ACS analysis
Seven cryopreserved donor-matched cAT-MSCs and cBM-MSCs
2  106 cells/donor) at passage 2 were analysed. The cells were
hawed on ice, washed in Hanks’ buffered saline solution (HBBS)
nd resuspended in stain buffer (FSB, BD Pharmingen) at a density
f 0.5–1  105 cells per reaction. Subsequently, the cells were
ncubated on ice in the dark for at least 15 min with canine-specific
hycoerythrin (PE), fluorescein isothiocyanate (FITC), or isotype
control antibodies (Table 1). After washing, the cells were stained
with 7-aminoactinomycin D (7AAD, 0.25 mg/test; BD Biosciences)
to differentiate between dead and live cells. Data were collected
using the FACS Diva software (v8.0) on a CANTO II (BD Biosciences)
and analysed using the FlowJo software (v10.0).
Chondrogenic differentiation
The protocol used for chondrogenic differentiation of the cMSCs
was adapted from Johnstone et al. (1998) and was first performed
using TGF-β1 (10 ng/mL, R and D Systems) and BMP-6 (10 ng/mL,
Peprotech; Hennig et al., 2007) in chondrogenic differentiation
medium (Dulbecco’s modified Eagle medium [DMEM] high
glucose, Invitrogen) containing 1% P/S, 1% ITS + premix (BD),
0.04 mg/mL proline (Sigma), 0.1 mM ascorbic acid 2-phosphate,
and 107 M dexamethasone (Sigma; Appendix A: Supplementary
material). Pellets were collected for reverse transcription-quanti-
tative polymerase chain reaction (RT-qPCR), glycosaminoglycan
(GAG), and DNA analyses, and immunohistochemical evaluation
after 35 days.
As this did not result in chondrogenic differentiation of the cAT-
MSCs, follow-up experiments were performed with higher
concentrations of BMP-6 and BMP-2 (10, 100, and 250 ng/mL).
RT-qPCR was performed after 7 days to detect early transcriptional
changes that precede the changes at the protein level. Additionally,
culture period of 21 days was used based on methods reported by
Mackay et al. (1998; Appendix A: Supplementary material).
GAG and DNA content
Three pellets per donor were pooled for each condition and
digested overnight at 60 C using 600 mL papain digestion solution
(11.9 mL/mL papain [Sigma] and 15.7 mg/mL cysteine HCl [Sigma]
in papain buffer [13 mg/mL H2NaPO4 2 H2O and 3.26 mg/mL EDTA,
pH 6]). GAG content was determined using dimethyl methylene
blue (DMMB, Sigma) assay as per protocols described previously
(Bach et al., 2015). DNA content was measured according to
manufacturer’s instructions with the QubitTM dsDNA HS assay
(ThermoFisher Scientific).
Immunohistochemical evaluation
Each pellet was fixed in 4% neutral buffered formalin (Klinipath
B.V.) with 0.1% eosin (Boom BV Memmel) and embedded in 2.4%
alginate and paraffin. Five-micrometre sections were stained for
Safranin O/Fast Green staining (0.125% Safranin O, Sigma; 0.4% Fast
Green, Sigma) and collagen type II (COL-II) and I (COL-I)
immunohistochemistry as per methods described previously
(Bach et al., 2015) using COL-I mouse monoclonal antibody
(0.07 mg/mL, Abcam, ab6308) and COL-II mouse monoclonal
antibody (0.02 mg/mL, DSSHB, II-II6B3), respectively. Normal
able 1
he antibodies used for FACS analysis.
Target Host Reactivity Clone Fluorochrome Manufacturer Catalog number
CD90 Rat Dog YKIX337.217 PE eBioscience 12-5900-42
CD73 Rabbit Human, Mouse, Rat, Dog, Chicken Unknown FITC Bioss antibodies bs-4834R
CD29 Mouse Human, Cow, Dog TS2/16 PE BioLegend 303004
CD271 Mouse Dog, Human, Mouse ME20.4 PE Invitrogen 12-9400-42
CD146 Mouse Dog, Human, Mouse, Rabbit P1H12 FITC Invitrogen 11-1469-42
CD45 Rat Dog Unknown PE LSBio LS-C127720
CD34 Mouse Dog IH6 PE BD Pharmingen 559369
Rat IgGK Rat Isotype control eB149/10H5 PE eBioscience 12-4031-82
Rabbit IgGk Rabbit Isotype control Unknown PE Antibodies online ABIN376422
Mouse IgGk Mouse Isotype control MOPC-21 PE BioLegend 400112
Gk, immunoglobulin kappa; PE, phycoerythrin; FITC, fluorescein isothiocyanate.
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Sections were stained for 5 min with Toluidine Blue O (0.04%,
Sigma; Basic Blue 17, 86% dye, dissolved in 0.2 M acetate buffer).
RT-qPCR analysis
The surface marker and chondrogenic gene expression profiles
were investigated in expansion passage 2 of five matched,
undifferentiated cAT-MSC and cBM-MSC donors (0.1  106 cells/
donor); the bone marrow was used as the control. The
chondrogenic gene expression of the differentiated cMSCs was
determined in three pooled pellets per donor for each condition.
The pellets were snap-frozen and crushed with a pestle (Argos
technologies Inc, 9951-901). Total RNA was isolated using the
RNeasy minikit (Qiagen, 74134) or microkit (Qiagen, 74004), which
included an on-column DNase step. RNA was quantified using the
NanoDrop ND-1000 spectophotometer (Isogen Life Science). cDNA
was synthesised using the iScriptTM cDNA synthesis kit (Bio-Rad)
according to the manufacturer’s instructions.
RT-qPCR was performed using the BioRad CFX-384 cycler and IQ
SYBRGreen supermix (Bio-Rad) and surface marker- and chon-
drogenic lineage-specific primers (Table 2). Relative expression
was estimated using the efficiency-corrected delta-delta Ct (DDCt)
method and six reference genes; HNRPH, RPL8, GUSB, SRPR, YWHAZ,
and sDHA (Table 2).
Statistical analysis
Detailed description of the statistical analyses using R software
(version 3.0.2) is provided in Appendix A: Supplementary material.
In short, linear mixed models were used for normally distributed
data and the Kruskal-Wallis rank sum test for data that were not
distributed normally. Differences were considered significant if P
values were <0.05 after multiple comparison correction. Addi-
tionally, the effect size (ES) was calculated using Cohen’s d (Cohen,
1977). Effect size of >0.8 was considered to be large, and >2.0 was
considered to be huge (Cohen, 1977; Sawilowsky, 2009).
Results
cBM-MSCs and cAT-MSCs were plastic-adherent and form colonies
All donors demonstrated the typical fibroblast-like phenotype
(Fig. 1). Approximately 80% confluency was reached within 5 days
for cAT-MSCs (range; 3–7 days) and within 8 days for cBM-MSCs
(range; 7–9 days). On average, cAT-MSCs and cBM-MSCs produced
Table 2
Primers used in RT-qPCR.
Marker Gene Primer Sequence Amplicon Size (bp) Annealing temperature (C) NCBI accession no.
Surface marker expression CD90 F: CAGCATGACCCGGGAGAAAAAG 134 63.5 NM_001287129
R:TGGTGGTGAAGCCGGATAAGTAGA
CD146 F: GGGAATGCTGAAGGAAGG 99 63 XM_022418207
R: CTTGGTGCTGAGGTTCTG
CD166 F: AAGCGTCATAAACCAAACAG 150 61 NM_001313804
R: TATAGCAGAGACATTCAAGGAG
CD73 F: CTCCAACACATTCCTTTACAC 150 61 XM_532221
R: ACTCAACCTTCAAATAGCCT
CD105 F: CATCCTTCACCACCAAGAG 139 60 XM_005625330
R: CAGATTGCAGAAGGACGG
CD44 F: CTTCTGCAGATCCGAACACA 147 60 NM_001197022
R: GAGTAGAAGCCGTTGGATGG
CD14 F: CCCGGCGCTCACCACCTTAGAC 98 60 XM_843653
R: CCTGGAGGGCCGGGAACTTTTG
CD45 F: GACCATGGGGTGCCTGAAGAT 90 5864 XM_005622282
R: CACAATGGGGCCACTGAAGAAG
CD31 F: GTTCTGCGTGTCAAGGTG 85 65 XM_022422841
R: TGTCCTTCCCAAACTCCA
CD34 F: TCAGGGCCCCCGACATCTC 115 66 NM_001003341
R: TCTCTGCTCACCCCTCTGGAAAAA
Chondrogenesis ACAN F: GGACACTCCTTGCAATTTGAG 110 6162 NM_001113455
R: GTCATTCCACTCTCCCTTCTC
COL2A1 F: GCAGCAAGAGCAAGGAC 150 60.565 NM_001006951
R: TTCTGAGAGCCCTCGGT
SOX9 F: CGCTCGCAGTACGACTACAC 105 6263 NM_001002978
R: GGGGTTCATGTAGGTGAAGG
COL1A1 F: GTGTGTACAGAACGGCCTCA 109 61 NM_001003090
R: TCGCAAATCACGTCATCG
COL10A1 F: CCAACACCAAGACACAG 80 61 XM_849417
R: CAGGAATACCTTGCTCTC
TGFβR1 F:CAGTCACCGAGACCACAGACAAAGT 100 54 XM_014117881
R:TGAAGATGGTGCACAAACAAATGG
House keeping genes HNRPH F: CTCACTATGATCCACCACG 151 61,2 XM_538576
R: TAGCCTCCATAACCTCCAC
RPL8 F: CCATGAATCCTGTGGAGC 64 55 XM_532360
R: GTAGAGGGTTTGCCGATG
GUSB F: AGACGCTTCCAAGTACCCC 103 62 NM_001003191
R: AGGTGTGGTGTAGAGGAGCAC
SRPR F: GCTTCAGGATCTGGACTGC 81 61,2 XM_546411
R: GTTCCCTTGGTAGCACTGG
YWHAZ F: CGAAGTTGCTGCTGGTGA 94 58 XM_843951
R: TTGCATTTCCTTTTTGCTGA
sDHA F: GCCTTGGATCTCTTGATGGA 92 61 DQ402985
R: TTCTTGGCTCTTATGCGATG
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no significant difference).
assage 2 cAT-MSCs had low CD73, ACAN, and SOX9 expression levels
The expression profile, investigated using FACS analysis, was
imilar for passage 2 cBM-MSCs and cAT-MSCs, with high
requencies of CD90+ and CD29+ cells and negligible number of
D271+, CD146+, CD34+, and CD45+ cells (Fig. 2a). The number of
D271+ cells were significantly lower in cAT-MSCs than that in
BM-MSCs (P < 0.001). Low but variable frequencies of CD73+ cells
ere observed (cBM-MSC: 17.7%  18.7%; cAT-MSC: 14.7%  8.8%).
RT-qPCR was performed to investigate the expression of surface
arkers, against which canine-specific FACS antibodies were not
vailable. High CD90, CD105, and CD166 expression and low CD146
xpression were observed in both cell types (Fig. 2b). CD44
xpression was low in cBM-MSCs and was undetectable in cAT-
SCs (P = 0.26). CD73 expression was significantly higher in cBM-
SC than that in cAT-MSC (P = 0.0088). CD34, CD45, CD14, and CD31
ere undetectable in both cell types. In undifferentiated cBM-
SCs, the expression levels of SOX9 (P = 0.02) and ACAN (P = 0.055)
ere higher than those in cAT-MSC (Fig. 2c). COL2A1 and COL1A1
ere similarly expressed in both cell types.
AT-MSCs did not undergo chondrogenesis without high
oncentrations of BMP-2 or BMP-6
in GAG deposition, observed only in cBM-MSCs (Fig. 3a), was
confirmed by increase in ACAN expression (P = 0.007, Fig. 3b) and
positivity to Safranin O and Toluidine Blue staining (Fig. 3c).
Deposition of COL-II by cBM-MSCs was confirmed using immuno-
histochemistry and was in agreement with the increase in COL2A1
expression (Fig. 3b and 3c). COL1A1 expression was significantly
upregulated in cBM-MSCs and cAT-MSCs upon addition of TGF-β1
alone (P = 0.00003) or with BMP-6 (P = 0.00003). Further, all cBM-
MSC and cAT-MSC donors expressed COL-I. Expression of TGFβR1
was significantly lower in cAT-MSCs than that in cBM-MSCs (P =
0.0008), and its expression did not increase with TGF-β1 or BMP-6
treatment. COL10A1 expression was not detected, irrespective of
the condition and donor.
Differentiation with TGF-β1 and different concentrations of BMP-2
and BMP-6
RT-qPCR was performed after 7 days to assess early transcrip-
tional changes (Fig. 4a). A BMP dose-dependent effect was
observed in cBM-MSCs, with significant increase in ACAN
expression upon addition of 100 or 250 ng/mL BMP-6 (P = 0.014
and 0.049, respectively), and 100 or 250 ng/mL BMP-2 (P = 0.0017
and 0.0059, respectively), compared to that in the control.
Additionally, compared to that in the control, COL2A1 expression
significantly increased with 100 and 250 ng/mL BMP-2 (P = 0.046
and 0.042, respectively), and 250 ng/mL BMP-6 (P = 0.049). In cAT-
MSCs, a moderate dose-dependent increase was observed only for
ig. 1. MSC morphology and CFU-F assays. (a) Bright light phase contrast images of canine bone marrow (BM)- and adipose tissue (AT)-derived mesenchymal stromal cells
MSC) demonstrate a typical fibroblast-like phenotype. Scale bars, 400 mM (b) Representative images of the colony-forming-units (CFU) assay after staining with Crystal
iolet; cAT-MSCs, 101  32 colonies; cBM-MSCs, 111  49 colonies per 1000 plated cells.ifferentiation with TGF-β1 and 10 ng/mL BMP-6 assessed at day 35
After addition of TGF-β1, DNA content increased in both cell
ypes (P = 0.00015) compared to that in the control group, without
dditional effect of BMP-6 (Fig. 3a). This was also reflected in the
ncrease in pellet size after TGF-β1 addition (Fig. 3c). The increase4
SOX9, ACAN, and COL1A1 after stimulation with BMP-2 or BMP-6.
TGFBR1 expression was significantly lower in cBM-MSCs treated
with 100 or 250 ng/mL BMP-6 (P < 0.001) than in those treated
with TGF-β1 alone. This downregulation was also significant for
cAT-MSCs in the presence of 250 ng/mL of BMP-6 (P = 0.02).
Expression of TGFBR1 in cAT-MSCs was significantly lower than
Fig. 2. Surface and chondrogenic marker expression in canine bone marrow (BM)- and adipose tissue (AT)-derived mesenchymal stromal cells (MSC) in passage 2. (a) Mean 
standard deviation (SD) of the percentage of cells positive for CD markers in cBM-MSCs (black bars) and cAT-MSCs (grey bars), assessed using FACS analysis. (b) Mean  SD of
the normalised relative expression of CD markers in the bone marrow (triangle), cBM-MSCs (circles), and cAT-MSCs (squares) compared to the mean gene expression (dotted
line). (c) Mean  SD of the normalised relative expression of ACAN, COL2A1, SOX9, and COL1A1 of cBM-MSCs (circles) and cAT-MSCs (squares) compared to the mean gene
expression (dotted line). Individual donors are shown in different colours. *, Significant difference between cell types within a gene or marker (* P < 0.05; ** P < 0.01). s,
Difference between the two cell types with P < 0.1 and an effect size > 0.8.
Fig. 3. Biochemical, histological, and RT-qPCR analyses of canine bone marrow (cBM, circles)- and canine adipose tissue (cAT, squares)-derived mesenchymal stromal cells
(MSC), differentiated towards the chondrogenic lineage for 35 days in pellet culture with or without 10 ng/mL TGF-β1 and 10 ng/mL BMP-6. (a) Biochemical analysis of the
glycosaminoglycan (GAG) content, DNA content, and GAG content corrected for DNA content (mean  standard deviation (SD)). (b) Mean  SD of the normalised relative
expression of ACAN, COL2A1, SOX9, COL1A1, and TGFBR1 compared to the mean expression of the control samples of both cell types (dotted line). Individual donors are shown in
different colours. ##, Significant difference in both cell types in this condition vs. the control group (P < 0.01); **, significant difference in the cBM-MSC group compared to that
in the cBM-MSC control group and the corresponding cAT-MSC group; P < 0.01. (c) Histological analysis of deposited glycosaminoglycans (GAG), using Safranin O/Fast Green
and Toluidine Blue, and immunohistochemical analysis of collagen type I and collagen type II. Scale bars, 200 mm.
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OL10A1 expression was not detected under any condition or with
ny donor.
After 21 days, GAG content and GAG/DNA increased signifi-
antly only after addition of 250 ng/mL BMP-2 to cBM-MSCs (P <
.01) and cAT-MSCs (P = 0.07; Fig. 4b). BMP-2 (100 ng/mL) induced
hondrogenesis only in a subset of the cBM-MSC and cAT-MSC
onors. GAG production and deposition was not observed after the
ddition of TGF-β1 or 10 ng/mL BMP-2/-6. Upon supplementation
ith 100 or 250 ng/mL BMP-6, chondrogenesis was limited to only
ne cBM-MSC donor. Irrespective of the growth factor supple-
ented, cBM-MSCs deposited more GAGs than cAT-MSCs. DNA
ontent significantly increased upon addition of 100 and 250 ng/
L BMP-2 (P < 0.01), demonstrated by the increase in pellet size
Fig. 4c). Positive Safranin O, Toluidine Blue, and COL-II staining
as observed in cBM-MSC pellets from donors that demonstrated
AG deposition at the biochemical level (Fig. 4c), while COL-II was
bsent in all cAT-MSCs (Fig. 4c). COL-I was deposited in pellets of all
onors after growth factor stimulation (Fig. 4c).
iscussion
AT-MSCs are commonly used in dogs for treating OA (Hoffman
nd Dow, 2016; Gugjoo et al., 2019) owing to their immune-
odulatory and regenerative abilities. However, their chondro-
enic potential remains unclear. Here, we further characterised
nd compared the surface marker expression and chondrogenic
otential of cAT-MSCs with those of cBM-MSCs, a reference
tandard.
A donor-matched comparison of MSC-related surface markers
emonstrated that the expression patterns of cBM-MSCs and cAT-
SCs were similar at passage 2. Differential expression was
bserved for CD73 and CD271, both poorly expressed in cAT-MSCs.
et al., 2020). The overall CD271+ frequency was lower in both cell
types than the frequencies reported in humans (Lv et al., 2014). The
cAT-MSC population contains a relatively lower fraction of cells
with chondrogenic potential, which possibly contributed to the
poor chondrogenesis observed in this study. However, CD marker
expression varies between reports and species (Uder et al., 2018);
more importantly, marker profiles change during passaging (Bara
et al., 2014), thereby rendering their predictive capacity of
chondrogenesis debatable. For example, CD34 expression is highly
affected by cell culture, which, while found to be high in cAT-MSCs
immediately after isolation, disappears after culture (Lin et al.,
2012). Furthermore, although CD34 expression has been reported
in cAT-MSCs (Russell et al., 2016; Kriston-Pál et al., 2017), our study
and studies reported by others (Ivanovska et al., 2017) have not
been able to detect it. Interpretation of the CD profiles was further
complicated by the previous finding that FACS-sorted subpopu-
lations of MSCs had similar CD marker expression profiles after
culturing, while retaining their functional differences (Sivasubra-
maniyan et al., 2018). In this complicated landscape, surface
marker characterisation in the veterinary field is further chal-
lenged by the lack of species-specific antibodies. Although RT-
qPCR analysis of CD markers can be used, discrepancies between
mRNA and protein expression should be considered. For example,
the canine MSCs were reportedly positive for CD44, while the gene
expression level of this CD marker was low. Altogether, this implies
that the applicability of the markers proposed by the International
Society for Cellular Therapy (ISCT; Dominici et al., 2006) in dogs
remains to be determined. Although CD marker expression was
largely similar, higher expression of ACAN and SOX9 in passage 2
undifferentiated cBM-MSCs was detected. We speculated that
these differences in gene expression were observed because cBM-
MSCs were more primed toward chondrogenesis than cAT-MSCs,
which was influenced by the tissue origin (Rasi Ghaemi et al.,
ig. 4. Biochemical, histological, and RT-qPCR analyses of the chondrogenic differentiation with or without different doses of bone morphogenetic protein (BMP)-2 or BMP-6
f canine bone marrow (cBM, circles)- and canine adipose tissue (cAT, squares)-derived mesenchymal stromal cells (MSC). (a) Mean  standard deviation (SD) of the
ormalised relative expression of ACAN, COL2A1, SOX9, COL1A1, and TGFBR1 of cBM-MSCs and cAT-MSCs differentiated towards the chondrogenic lineage for 7 days in pellet
ulture with or without TGF-β1 and 10, 100, or 250 ng/mL BMP-2 or BMP-6. Gene expression has been presented as the expression compared to the mean gene expression of
he control samples of both cell types (dotted line). Individual donors are shown in different colours. #, significant difference between all cell types in this condition and the
ontrol group (#, P < 0.05; ##, P < 0.01); *, significant difference vs. the control group, but only in this cell type (*, P < 0.05; **, P < 0.01); $, significant difference vs. the group
reated with only TGF-β1 for cBM-MSCs (COL1a1, TGFβR1), cAT-MSCs (ACAN), or independent of cell type (DNA content; P < 0.05); &, significant difference between cell types
ithin the same condition (P < 0.05). (b) Biochemical analysis of the glycosaminoglycan (GAG) content, DNA content, and GAG content corrected for DNA content (mean  SD)
f cBM-MSC and cAT-MSC, differentiated toward the chondrogenic lineage for 21 days in pellet culture with or without TGF-β1 and 10, 100, or 250 ng/mL BMP-2 or BMP-6. (c)
istological analysis of glycosaminoglycans (GAG), using Safranin O/Fast Green and Toluidine Blue, and immunohistochemical analysis of collagen I and collagen II.D73 positivity in hAT-MSCs has been associated with high
hondrogenic capacity and low osteogenic capacity (Rada et al.,
011). CD271 is considered a highly selective surface marker for
BM-MSCs; CD271+ cells are considered to possess higher
hondrogenic potential (Lv et al., 2014; Somoza et al., 2014; Lu6
2013). However, further investigation regarding the chondrogenic
potential of specific subpopulations within cBM-MSCs or cAT-
MSCs is warranted.
Ideally, upon chondrogenic differentiation, cMSCs should
primarily produce COL-II rather than COL-I. Our results
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II being primarily produced under effective chondrogenic con-
ditions, which was in agreement with the observations reported by
other studies (Hodgkiss-Geere et al., 2012), while cAT-MSCs only
deposited COL-I under the same culture conditions. Contrarily,
COL-II deposition in cAT-MSC pellets has been demonstrated by
others (Neupane et al., 2008; Vieira et al., 2010). However, a few
studies that directly compared cBM- and cAT-MSCs reported that
cAT-MSCs expressed less COL2A1 (Reich et al., 2012) and exhibited
limited COL-II and Toluidine Blue staining (Bearden et al., 2017)
without BMP supplementation. COL-I deposition by both cMSCs is
not remarkable, as TGF-β1 is known to exert fibrotic effects
(Cutroneo, 2007). In the absence of sufficient chondrogenic
stimuli, cMSCs produce a more fibrous instead of hyaline-based
cartilaginous matrix, explaining the increase in pellet size in all
TGF-β1-stimulated pellets. Furthermore, within the course of
chondrogenic differentiation, hMSCs follow the endochondral
ossification pathway, thereby expressing markers of hypertrophy
(COL-X, ALP, and MMP13; Pelttari et al., 2008). In this study, COL-X
was undetectable at the gene and protein levels. Whether cMSCs
eventually also undergo hypertrophic differentiation when cul-
tured for extended periods of time or whether additional stimuli
are necessary remains to be determined.
The chondrogenic potential of human AT-MSCs may depend on
growth factors other than TGF-β1 (Hennig et al., 2007). However,
cAT-MSCs did not undergo chondrogenesis with the addition of 10
ng/mL BMP-6, nor was there COL-II deposition with higher doses of
BMP-2/-6. Additionally, TGFβR1, which was reported to restore the
chondrogenic potential of hAT-MSCs, was significantly down-
regulated in cAT-MSCs supplemented with high doses of BMP. This
downregulation is probably the result of negative feedback loops
initiated by the high BMP concentration that act at the receptor
level (Yan et al., 2018). The discrepancy in outcome between this
study and other studies might be due to culture protocol and/or
species differences (Martínez-Lorenzo et al., 2009). In contrast to
sheep or human chondrocytes, canine chondrocytes lose their
ability to re-differentiate under chondrogenic induction after few
passages (Giannoni et al., 2005). Alternative growth factors might
therefore be required to restore the chondrogenic potential of cAT-
MSCs (Boeuf and Richter, 2010). It is also possible that environ-
mental factors arising during culture, such as mechanical
stimulation, oxygen tension, and nutritional supplementation,
may explain why the results of this study differ from those of other
studies (Hennig et al., 2007; Neupane et al., 2008; Vieira et al.,
2010), and their effect on cAT-MSCs should be further investigated.
Conclusions
This study demonstrated that the chondrogenic capacity of cAT-
MSCs under standard culture conditions was inferior to that of
cBM-MSCs, as demonstrated by the deposition of GAGs and COL-II,
and that chondrogenic capacity could not be restored with
different doses of BMP-2 or BMP-6. Further investigation of the
stimuli necessary for the chondrogenic differentiation of cAT-MSCs
is warranted before considering cAT-MSCs for cell-based treatment
strategies for OA.
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